Jun 01, 2020
Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update
May 28, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
May 26, 2020
German Respiratory Devices Market, Forecast to 2025 - Focus on Therapeutic Devices, Diagnostic & Monitoring Devices, Consumables & Accessories
Apr 21, 2020
Italian Respiratory Devices Industry Assessment 2020 with Bayer, ResMed, Chiesi Farmaceutici, GlaxoSmithKline, Novartis, and Boehringer Ingelheim Dominating
Apr 21, 2020
Europe's Respiratory Devices Industry, 2020 Insights - Therapeutic Devices, Diagnostic & Monitoring Devices, and Consumable & Accessories
Mar 18, 2020
Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement
Feb 27, 2020
Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020
Feb 06, 2020
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Feb 06, 2020
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
Nov 18, 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
Nov 07, 2019
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
Sep 24, 2019
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease
Oct 31, 2018
Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S
Aug 16, 2017
Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017
Jun 06, 2017
Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China